Definium Therapeutics (NASDAQ:DFTX) Stock Rating Upgraded by Wall Street Zen

Definium Therapeutics (NASDAQ:DFTX) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

DFTX has been the topic of a number of other reports. Oppenheimer set a $60.00 target price on shares of Definium Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 22nd. JonesTrading increased their price objective on Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a research note on Wednesday, June 24th. Royal Bank Of Canada restated an “outperform” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Robert W. Baird lifted their target price on Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, June 23rd. Finally, Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $46.92.

Definium Therapeutics Stock Performance

NASDAQ DFTX opened at $44.19 on Friday. The stock has a market cap of $4.41 billion, a PE ratio of -17.75 and a beta of 2.20. Definium Therapeutics has a 12 month low of $6.95 and a 12 month high of $49.20. The company’s 50-day moving average price is $26.79 and its 200-day moving average price is $20.50. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Equities research analysts forecast that Definium Therapeutics will post -2.29 earnings per share for the current year.

Insider Buying and Selling at Definium Therapeutics

In other news, insider Matthew T. Wiley sold 2,867 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the transaction, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. This trade represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the transaction, the insider directly owned 320,571 shares in the company, valued at approximately $14,435,312.13. The trade was a 3.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 48,096 shares of company stock worth $2,165,763. 2.40% of the stock is owned by company insiders.

Institutional Trading of Definium Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Commodore Capital LP increased its holdings in shares of Definium Therapeutics by 10.5% in the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after acquiring an additional 475,000 shares during the period. Orbimed Advisors LLC purchased a new stake in shares of Definium Therapeutics during the 3rd quarter worth $4,337,000. Rosalind Advisors Inc. boosted its position in Definium Therapeutics by 78.6% during the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock valued at $8,842,000 after purchasing an additional 330,000 shares in the last quarter. Two Sigma Investments LP boosted its position in Definium Therapeutics by 424.9% during the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock valued at $3,495,000 after purchasing an additional 239,965 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Definium Therapeutics by 11.0% during the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after purchasing an additional 198,878 shares in the last quarter. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.